Anebulo Pharmaceuticals Inc

NASDAQ ANEB

Download Data

Anebulo Pharmaceuticals Inc Net Income Before Taxes 5 year CAGR for the quarter ending March 31, 2024

Anebulo Pharmaceuticals Inc Net Income Before Taxes 5 year CAGR is NA for the quarter ending March 31, 2024. Net income before taxes represents a company's profit after all operating expenses and interest expenses have been deducted but before taxes have been accounted for. It is calculated by dividing the net income by (1 - tax rate). This metric helps evaluate the company's profitability and assess its earnings before the impact of tax obligations. It provides insights into the company's pre-tax financial performance and is often used for comparing companies in different tax jurisdictions. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Anebulo Pharmaceuticals Inc Net Income Before Taxes for the quarter ending March 31, 2023 was -2,797,971.00, a -49.11% change year over year.
  • Anebulo Pharmaceuticals Inc Net Income Before Taxes for the quarter ending March 31, 2022 was -1,876,491.00.
NASDAQ: ANEB

Anebulo Pharmaceuticals Inc

CEO Dr. Joseph F. Lawler M.D., Ph.D.
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South, Lakeway, TX, United States, 78734
Employees 2
Sector Healthcare
Industry Biotechnology
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email